ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1755

Multi-Omic Profiling Of CD8+ T Cells In Axial Spondyloarthritis (axSpA) And Reactive Arthritis (ReA) Implicates Common Pathways

Zoya Qaiyum1, Michael Tang2, Shirin Soleimani3, Addison Pacheco2, Melissa Lim4, Fataneh Tavasolian4, Trevor Pugh3 and Robert Inman2, 1Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, 2University Health Network, Toronto, ON, Canada, 3Princess Margaret Cancer Centre, University Health Network, Toronto, Canada, 4University of Toronto, Toronto, ON, Canada

Meeting: ACR Convergence 2025

Keywords: genomics, immunology, interferon, spondyloarthritis, T-Lymphocyte

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Basic Science (1752–1757)

Session Type: Abstract Session

Session Time: 10:45AM-11:00AM

Background/Purpose: The strong clinical and genetic associations between axial spondyloarthritis (axSpA) and inflammatory bowel disease (IBD) underscore the pathogenic role of the gut-joint axis. We previously identified a subpopulation of pathogenic mature CD8+ T cells in the axSpA synovial fluid (SF), expressing CD103+ and CD49a+ integrins (InEx cells). The expression of integrins on InEx cells implicates their role in aberrant migration between the gut-joint axis. Whether InEx cells recognize an arthritogenic peptide remains unclear. We hypothesize that InEx cells may incite and perpetuate chronic inflammation in axSpA. To this end, we characterized their T-cell receptor (TCR) repertoire and gene expression profile.

Methods: Patients fulfilling the ASAS classification for axSpA were recruited (n=4). Active joint effusion from these patients is reflective of active joint inflammation which coincided with high disease activity (BASDAI >4). We isolated peripheral blood mononuclear cells (PBMCs) and synovial fluid mononuclear cells (SFMCs), followed by FACS-sorting of mature CD8+ T cells and InEx cells. Subsequently, single-cell TCR (paired ab chains) and RNA sequencing were performed on these cell types. An HLA-B27+ reactive arthritis (ReA) sample were used as a comparison. These were all compared to HLA-B27+ healthy controls (n=4). Additionally, we used the GLIPH2 computational tool to assess TCR sequence convergence based on shared motifs to infer antigen-specific TCR groups.

Results: 12 distinct clusters of mature CD8+ T cells from all samples were observed, exhibiting gene expression consistent with TRM-like, cytotoxic and interferon-stimulated gene (ISG) potential. axSpA InEx cells showed a preferential expression of clusters associated with ISG expression and proliferation vs ReA mature CD8+ T cells, as judged by high IFIT1, IFIT3, MX1, and MKI67 transcripts. Increased cytotoxic potential, based on elevated GZMA and GZMB, with some suppressive capacity, based on elevated IL2RA, FOXP3, and CTLA4, was also observed in axSpA InEx cells. The axSpA InEx TCR repertoire was less diverse, clonally expanded, and demonstrated specific TRBV9_TRAV27, TRBV9_TRAV8-2, and TRBV7-8_TRAV3 gene usage vs mature CD8+ T cells from either axSpA PB or SF. However, axSpA InEx cells demonstrated similarities with ReA mature CD8+ T cells, based on TCR gene usage (TRBV20-1_TRAV1-2, TRBV6-1_TRAV1-2, and TRBV6-2_TRAV1-2) and CDR3b motifs.

Conclusion: These observations suggest that InEx cells may incite inflammation similarly to ReA due to potential recognition of similar peptides, ultimately driving the selection of specific T cell clones. However, InEx cells represent a hybrid tissue resident memory-like population, likely primed by chronic type I interferon exposure. This may underlie the functional capacity of their clonal expansion and their ability to perpetuate inflammation which is distinct from ReA. This has important implications for therapeutic designs attempting to target integrin blockade in axSpA.

Supporting image 1Left panel displaying transcriptome profile of InEx vs mature CD8+ ReA SFMCs on UMAP plots. Genetic profile of InEx cells cluster differently to ReA SF. Right panel displaying notable gene expression across all groups, particularly in InEx and ReA SFMC. UMAP = Uniform Manifold Approximation and Projection, SF = synovial fluid, HC = healthy controls.

Supporting image 2Left panel displaying the V gene frequency (% total cells in the group) of paired TRAV_TRBV genes expanded in InEx cells vs axSpA PBMC. Right panel displaying the CDR3b sequence logo plots between InEx and ReA SF mature CD8 T cells. Yellow stars highlight the amino acids that differ between the two groups.


Disclosures: Z. Qaiyum: None; M. Tang: None; S. Soleimani: None; A. Pacheco: None; M. Lim: None; F. Tavasolian: None; T. Pugh: AstraZeneca, 2, 5, Chrysalis Biomedical Advisors, 2, Dynacare, 10, Merck, 2, Roche/Genentech, 2, 5; R. Inman: AbbVie/Abbott, 2, Janssen, 2, Novartis, 2, 5, UCB, 2, 5.

To cite this abstract in AMA style:

Qaiyum Z, Tang M, Soleimani S, Pacheco A, Lim M, Tavasolian F, Pugh T, Inman R. Multi-Omic Profiling Of CD8+ T Cells In Axial Spondyloarthritis (axSpA) And Reactive Arthritis (ReA) Implicates Common Pathways [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/multi-omic-profiling-of-cd8-t-cells-in-axial-spondyloarthritis-axspa-and-reactive-arthritis-rea-implicates-common-pathways/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/multi-omic-profiling-of-cd8-t-cells-in-axial-spondyloarthritis-axspa-and-reactive-arthritis-rea-implicates-common-pathways/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology